# A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

> **NCT03557099** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 55 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Hetrombopag Olamine

## Key facts

- **NCT ID:** NCT03557099
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2019-10-31
- **Final completion:** 2020-07-23
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557099, "A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03557099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*